|
|
|
[¸ðÁý°³¿ä] |
ȸ»ç : |
¿Ü±¹°èÁ¦¾àȸ»ç |
Æ÷Áö¼Ç : |
PV-CR Associate |
ȸ»çÀ§Ä¡ : |
¼¿ï |
[¸ðÁýºÎ¹®] |
Á÷À§ : |
´ë¸®±Þ |
´ã´ç¾÷¹« : |
PV – CR(Clinical research) Associate/¿Ü±¹°èÁ¦¾àȸ»ç
¿Ü±¹°è Á¦¾àȸ»ç¿¡¼ PV – CR(Clinical research) Associate ¸¦ ã°í °è½Ê´Ï´Ù.
ÁÖ¿ä ¾÷¹«´Â ¾Æ·¡¿Í °°½À´Ï´Ù.
Main Accountability
• Manage collection, processing, documentation, reporting and follow-up of all adverse event (AE) reports and adverse drug reactions (ADR) for all the Company¡¯s products from clinical trials, post-marketing studies (PMS), Spontaneous Reports (SR), registries, commercial programs, etc.
• Ensure recording and tracking of receipts/submissions/distributions of Individual Case Safety Reports (ICSR), Serious Adverse Events (SAEs), Investigator Notifications (IN), Periodic Safety Report Updates (PSUR) and Annual Safety Reports (ASR) and ensure reporting/submission/distribution of safety re-ports/updates/information (e.g. ICSR, SAE, IN, PSUR ASR, changes in risk benefit) to local Health Au-thorities (HA) according to regulatory requirements.
• Management and maintenance all local relevant PV databases.
• Ensure appropriate agreements are in place for local licensor or licensee to comply with all require-ment for reporting ADRs/AEs.
• Participate in local/regional clinical operations activities and local business meetings as required.
• Interact with CRO s and develop alliance with preferable CROs for ensuring qualified clinical operation.
• Supervise overall project performance in a team and ensure qualities through co-visit and co-monitoring.
• Responsible for implementing of assigned clinical trials as a project owner.
• Manage and support CRA s in all clinical operation activities and issues.
|
°æ·Â¿ä°Ç : |
Requirements :
1. PV°æ·Â 2³âÀÌ»óÀÇ ºÐ
2. PV + CR °æ·Â °¡Áö°í °è½ÅºÐ ¼±È£ÇÕ´Ï´Ù.
3. ¾àÇÐÀü°øÀÚ
4. ¿µ¾î °¡´ÉÇϽŠºÐ
|
¿¬·É : |
. |
Çз : |
. |
¾îÇÐ : |
. |
ÄÄÇ»ÅÍ : |
. |
¿¬ºÀ : |
. |
ƯÀÌ»çÇ× : |
. |
[´ã´çÀÚ/¹®ÀÇó] |
´ã´çÀÚ : |
¿øÇö¼÷»ó¹« |
ÀüÈ : |
02-2050-0299 |
Á¦Ãâ¼·ù : |
±¹¿µ¹®À̷¼ |
ÀüÀÚ¿ìÆí : |
hs@mstone.co.kr |
|
|
|
|